Akero Therapeutics, Inc. (AKRO) 10-Year Financial Performance & Capital Metrics

AKRO • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Show more

Revenue $0
EBITDA -$285M -65.1%
Net Income -$252M -66.1%
EPS (Diluted) -3.75 -29.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -39.22% -11.4%
ROIC -55.33% +11.4%
Debt/Equity 0.05 -1.1%
Interest Coverage -61.14 -9.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 27.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.27%

ROCE

10Y Avg-167.81%

5Y Avg-42.85%

3Y Avg-42.06%

Latest-42.37%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	213K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-213K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	1%	-	-	-
Operating Expenses+	4.56M	13.78M	45.65M	80.15M	100.89M	115.16M	172.87M	285.42M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.08M	1.9M	8.61M	15.24M	19.13M	29.87M	31.07M	37.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	3.49M	11.88M	37.05M	64.92M	81.76M	85.28M	141.8M	247.5M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-4.56M	-13.78M	-45.65M	-80.15M	-100.89M	-115.16M	-172.87M	-285.42M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.02%	-2.31%	-0.76%	-0.26%	-0.14%	-0.5%	-0.65%
EBITDA+	414.91K	0	-45.76M	-79.94M	-100.84M	-115.11M	-172.84M	-285.4M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1%	-	-0.75%	-0.26%	-0.14%	-0.5%	-0.65%
D&A (Non-Cash Add-back)	4.98M	13.78M	-104K	213K	41K	43K	29K	18K
EBIT	-4.56M	-81.71M	-43.73M	-79.21M	-100.78M	-111.29M	-148.66M	-247.39M
Net Interest Income+	0	0	1.9M	947K	109K	3.12M	21.11M	33.36M
Interest Income	0	0	1.9M	947K	109K	3.86M	24.21M	38.03M
Interest Expense	0	0	0	0	0	739K	3.1M	4.67M
Other Income/Expense	0	-67.94M	1.9M	947K	109K	3.12M	21.11M	33.36M
Pretax Income+	-4.56M	-81.71M	-43.76M	-79.21M	-100.78M	-112.03M	-151.76M	-252.06M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-17K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.56M	-81.71M	-43.76M	-79.19M	-100.78M	-112.03M	-151.76M	-252.06M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-16.9%	0.46%	-0.81%	-0.27%	-0.11%	-0.35%	-0.66%
Net Income (Continuing)	-4.56M	-81.71M	-43.76M	-79.19M	-100.78M	-112.03M	-151.76M	-252.06M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.16	-3.85	-2.90	-2.52	-2.89	-2.87	-2.89	-3.75
EPS Growth %	-	-23.06%	0.25%	0.13%	-0.15%	0.01%	-0.01%	-0.3%
EPS (Basic)	-0.16	-3.85	-2.90	-2.52	-2.89	-2.87	-2.89	-3.75
Diluted Shares Outstanding	28.56M	21.22M	15.07M	31.46M	34.83M	38.98M	52.57M	67.14M
Basic Shares Outstanding	28.56M	21.22M	15.07M	31.46M	34.83M	38.98M	52.57M	67.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	638K	77.13M	138.05M	271.35M	193.58M	355.17M	559.96M	770.38M
Cash & Short-Term Investments	598K	75.97M	136.4M	268.39M	188.26M	351.45M	550.01M	743.08M
Cash Only	598K	75.97M	64.79M	187.24M	150.48M	249.77M	234.21M	340.24M
Short-Term Investments	0	0	71.61M	81.14M	37.77M	101.68M	315.8M	402.84M
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	40K	1.16M	0	0	0	0	9.95M	27.3M
Total Non-Current Assets+	20K	20K	69K	1.99M	1.97M	1.4M	20.31M	55.51M
Property, Plant & Equipment	0	0	0	1.79M	1.55M	1.29M	1.03M	755K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	20K	20K	0	0	0	0	19.28M	54.75M
Other Non-Current Assets	0	0	69K	201K	417K	108K	0	0
Total Assets+	658K	77.15M	138.12M	273.34M	195.55M	356.57M	580.27M	825.89M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	116.25%	0.79%	0.98%	-0.28%	0.82%	0.63%	0.42%
Total Current Liabilities+	222K	2.34M	9.37M	13.11M	25.13M	19.08M	19.13M	39.75M
Accounts Payable	60K	1.37M	947K	3.43M	6.71M	7.97M	7.04M	9.03M
Days Payables Outstanding	-	-	-	5.87K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	2K	665K	1.61M	495K	554K	9.99M	1.3M	1.17M
Current Ratio	2.87x	32.93x	14.73x	20.70x	7.70x	18.61x	29.27x	19.38x
Quick Ratio	2.87x	32.93x	14.73x	20.70x	7.70x	18.61x	29.27x	19.38x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	124.73M	23K	1.52M	1.31M	10.93M	25.84M	36.02M
Long-Term Debt	0	0	0	0	0	9.54M	24.96M	35.3M
Capital Lease Obligations	0	0	0	1.52M	1.31M	1.08M	819K	529K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	5M	124.73M	23K	0	0	305K	54K	194K
Total Liabilities	5.22M	127.07M	9.39M	14.63M	26.44M	30.01M	44.97M	75.77M
Total Debt+	0	0	85K	1.81M	1.52M	10.95M	26.3M	36.46M
Net Debt	-598K	-75.97M	-64.7M	-185.43M	-148.97M	-238.83M	-207.9M	-303.78M
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.03x	0.05x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-1.44x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-155.83x	-55.78x	-61.14x
Total Equity+	-4.56M	-49.92M	128.73M	258.71M	169.11M	326.56M	535.31M	750.11M
Equity Growth %	-	-9.94%	3.58%	1.01%	-0.35%	0.93%	0.64%	0.4%
Book Value per Share	-0.16	-2.35	8.54	8.22	4.86	8.38	10.18	11.17
Total Shareholders' Equity	-4.56M	-49.92M	128.73M	258.71M	169.11M	326.56M	535.31M	750.11M
Common Stock	0	0	3K	4K	4K	5K	6K	7K
Retained Earnings	-4.56M	-86.56M	-130.32M	-209.53M	-310.3M	-422.34M	-574.1M	-826.16M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-6K	-3K	-27K	37K	270K	948K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.38M	-4.63M	-35.63M	-70.8M	-79.68M	-92.52M	-145.37M	-230.11M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.06%	-6.7%	-0.99%	-0.13%	-0.16%	-0.57%	-0.58%
Net Income	-4.56M	-81.71M	-43.76M	-79.21M	-100.78M	-112.03M	-151.76M	-252.06M
Depreciation & Amortization	0	0	-104K	17K	41K	43K	29K	18K
Stock-Based Compensation	0	121K	1.77M	6.02M	10.05M	23.24M	21.5M	29.7M
Deferred Taxes	0	0	104K	83K	1.07M	0	0	0
Other Non-Cash Items	-60K	75.91M	-104K	196K	203K	689K	-8.46M	-10.76M
Working Capital Changes	182K	1.06M	6.46M	2.08M	9.73M	-4.46M	-6.67M	3M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	60K	1.31M	-426K	2.48M	3.27M	968K	-645K	2.01M
Cash from Investing+	0	-5M	-71.51M	-9.76M	42.28M	-63.83M	-223.62M	-109.71M
Capital Expenditures	0	-5M	0	-148K	0	0	0	-999K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-5K	0	-9.61K	0	0	0	0
Cash from Financing+	5M	85.01M	95.99M	203.11M	602K	255.63M	353.32M	445.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	5M	-493K	536K	553K	0	4.43M	2.89M	12.77M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.38M	-9.63M	-35.63M	-70.95M	-79.68M	-92.52M	-145.37M	-231.11M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.2%	-2.7%	-0.99%	-0.12%	-0.16%	-0.57%	-0.59%
FCF per Share	-0.15	-0.45	-2.36	-2.26	-2.29	-2.37	-2.77	-3.44
FCF Conversion (FCF/Net Income)	0.96x	0.06x	0.81x	0.89x	0.79x	0.83x	0.96x	0.91x
Interest Paid	0	0	0	0	0	0	0	3.98M
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-111.04%	-40.88%	-47.11%	-45.2%	-35.22%	-39.22%
Return on Invested Capital (ROIC)	-	-	-	-87.57%	-161.98%	-160.12%	-62.46%	-55.33%
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.03x	0.05x	0.05x
Interest Coverage	-	-	-	-	-	-155.83x	-55.78x	-61.14x
FCF Conversion	0.96x	0.06x	0.81x	0.89x	0.79x	0.83x	0.96x	0.91x

Frequently Asked Questions

Growth & Financials

Akero Therapeutics, Inc. (AKRO) grew revenue by 0.0% over the past year. Growth has been modest.

Akero Therapeutics, Inc. (AKRO) reported a net loss of $292.8M for fiscal year 2024.

Dividend & Returns

Akero Therapeutics, Inc. (AKRO) has a return on equity (ROE) of -39.2%. Negative ROE indicates the company is unprofitable.

Akero Therapeutics, Inc. (AKRO) had negative free cash flow of $250.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Akero Therapeutics, Inc. (AKRO) 10-Year Financial Performance & Capital Metrics

AKRO • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$285M -65.1%
Net Income -$252M -66.1%
EPS (Diluted) -3.75 -29.8%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -39.22% -11.4%
ROIC -55.33% +11.4%
Debt/Equity 0.05 -1.1%
Interest Coverage -61.14 -9.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 27.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.27%

ROCE

10Y Avg-167.81%

5Y Avg-42.85%

3Y Avg-42.06%

Latest-42.37%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	213K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-213K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	1%	-	-	-
Operating Expenses+	4.56M	13.78M	45.65M	80.15M	100.89M	115.16M	172.87M	285.42M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	1.08M	1.9M	8.61M	15.24M	19.13M	29.87M	31.07M	37.93M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	3.49M	11.88M	37.05M	64.92M	81.76M	85.28M	141.8M	247.5M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-4.56M	-13.78M	-45.65M	-80.15M	-100.89M	-115.16M	-172.87M	-285.42M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.02%	-2.31%	-0.76%	-0.26%	-0.14%	-0.5%	-0.65%
EBITDA+	414.91K	0	-45.76M	-79.94M	-100.84M	-115.11M	-172.84M	-285.4M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1%	-	-0.75%	-0.26%	-0.14%	-0.5%	-0.65%
D&A (Non-Cash Add-back)	4.98M	13.78M	-104K	213K	41K	43K	29K	18K
EBIT	-4.56M	-81.71M	-43.73M	-79.21M	-100.78M	-111.29M	-148.66M	-247.39M
Net Interest Income+	0	0	1.9M	947K	109K	3.12M	21.11M	33.36M
Interest Income	0	0	1.9M	947K	109K	3.86M	24.21M	38.03M
Interest Expense	0	0	0	0	0	739K	3.1M	4.67M
Other Income/Expense	0	-67.94M	1.9M	947K	109K	3.12M	21.11M	33.36M
Pretax Income+	-4.56M	-81.71M	-43.76M	-79.21M	-100.78M	-112.03M	-151.76M	-252.06M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	-17K	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.56M	-81.71M	-43.76M	-79.19M	-100.78M	-112.03M	-151.76M	-252.06M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-16.9%	0.46%	-0.81%	-0.27%	-0.11%	-0.35%	-0.66%
Net Income (Continuing)	-4.56M	-81.71M	-43.76M	-79.19M	-100.78M	-112.03M	-151.76M	-252.06M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.16	-3.85	-2.90	-2.52	-2.89	-2.87	-2.89	-3.75
EPS Growth %	-	-23.06%	0.25%	0.13%	-0.15%	0.01%	-0.01%	-0.3%
EPS (Basic)	-0.16	-3.85	-2.90	-2.52	-2.89	-2.87	-2.89	-3.75
Diluted Shares Outstanding	28.56M	21.22M	15.07M	31.46M	34.83M	38.98M	52.57M	67.14M
Basic Shares Outstanding	28.56M	21.22M	15.07M	31.46M	34.83M	38.98M	52.57M	67.14M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	638K	77.13M	138.05M	271.35M	193.58M	355.17M	559.96M	770.38M
Cash & Short-Term Investments	598K	75.97M	136.4M	268.39M	188.26M	351.45M	550.01M	743.08M
Cash Only	598K	75.97M	64.79M	187.24M	150.48M	249.77M	234.21M	340.24M
Short-Term Investments	0	0	71.61M	81.14M	37.77M	101.68M	315.8M	402.84M
Accounts Receivable	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	40K	1.16M	0	0	0	0	9.95M	27.3M
Total Non-Current Assets+	20K	20K	69K	1.99M	1.97M	1.4M	20.31M	55.51M
Property, Plant & Equipment	0	0	0	1.79M	1.55M	1.29M	1.03M	755K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	20K	20K	0	0	0	0	19.28M	54.75M
Other Non-Current Assets	0	0	69K	201K	417K	108K	0	0
Total Assets+	658K	77.15M	138.12M	273.34M	195.55M	356.57M	580.27M	825.89M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	116.25%	0.79%	0.98%	-0.28%	0.82%	0.63%	0.42%
Total Current Liabilities+	222K	2.34M	9.37M	13.11M	25.13M	19.08M	19.13M	39.75M
Accounts Payable	60K	1.37M	947K	3.43M	6.71M	7.97M	7.04M	9.03M
Days Payables Outstanding	-	-	-	5.87K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	2K	665K	1.61M	495K	554K	9.99M	1.3M	1.17M
Current Ratio	2.87x	32.93x	14.73x	20.70x	7.70x	18.61x	29.27x	19.38x
Quick Ratio	2.87x	32.93x	14.73x	20.70x	7.70x	18.61x	29.27x	19.38x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	5M	124.73M	23K	1.52M	1.31M	10.93M	25.84M	36.02M
Long-Term Debt	0	0	0	0	0	9.54M	24.96M	35.3M
Capital Lease Obligations	0	0	0	1.52M	1.31M	1.08M	819K	529K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	5M	124.73M	23K	0	0	305K	54K	194K
Total Liabilities	5.22M	127.07M	9.39M	14.63M	26.44M	30.01M	44.97M	75.77M
Total Debt+	0	0	85K	1.81M	1.52M	10.95M	26.3M	36.46M
Net Debt	-598K	-75.97M	-64.7M	-185.43M	-148.97M	-238.83M	-207.9M	-303.78M
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.03x	0.05x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-1.44x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-155.83x	-55.78x	-61.14x
Total Equity+	-4.56M	-49.92M	128.73M	258.71M	169.11M	326.56M	535.31M	750.11M
Equity Growth %	-	-9.94%	3.58%	1.01%	-0.35%	0.93%	0.64%	0.4%
Book Value per Share	-0.16	-2.35	8.54	8.22	4.86	8.38	10.18	11.17
Total Shareholders' Equity	-4.56M	-49.92M	128.73M	258.71M	169.11M	326.56M	535.31M	750.11M
Common Stock	0	0	3K	4K	4K	5K	6K	7K
Retained Earnings	-4.56M	-86.56M	-130.32M	-209.53M	-310.3M	-422.34M	-574.1M	-826.16M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-6K	-3K	-27K	37K	270K	948K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.38M	-4.63M	-35.63M	-70.8M	-79.68M	-92.52M	-145.37M	-230.11M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.06%	-6.7%	-0.99%	-0.13%	-0.16%	-0.57%	-0.58%
Net Income	-4.56M	-81.71M	-43.76M	-79.21M	-100.78M	-112.03M	-151.76M	-252.06M
Depreciation & Amortization	0	0	-104K	17K	41K	43K	29K	18K
Stock-Based Compensation	0	121K	1.77M	6.02M	10.05M	23.24M	21.5M	29.7M
Deferred Taxes	0	0	104K	83K	1.07M	0	0	0
Other Non-Cash Items	-60K	75.91M	-104K	196K	203K	689K	-8.46M	-10.76M
Working Capital Changes	182K	1.06M	6.46M	2.08M	9.73M	-4.46M	-6.67M	3M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	60K	1.31M	-426K	2.48M	3.27M	968K	-645K	2.01M
Cash from Investing+	0	-5M	-71.51M	-9.76M	42.28M	-63.83M	-223.62M	-109.71M
Capital Expenditures	0	-5M	0	-148K	0	0	0	-999K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-5K	0	-9.61K	0	0	0	0
Cash from Financing+	5M	85.01M	95.99M	203.11M	602K	255.63M	353.32M	445.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	5M	-493K	536K	553K	0	4.43M	2.89M	12.77M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.38M	-9.63M	-35.63M	-70.95M	-79.68M	-92.52M	-145.37M	-231.11M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.2%	-2.7%	-0.99%	-0.12%	-0.16%	-0.57%	-0.59%
FCF per Share	-0.15	-0.45	-2.36	-2.26	-2.29	-2.37	-2.77	-3.44
FCF Conversion (FCF/Net Income)	0.96x	0.06x	0.81x	0.89x	0.79x	0.83x	0.96x	0.91x
Interest Paid	0	0	0	0	0	0	0	3.98M
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-111.04%	-40.88%	-47.11%	-45.2%	-35.22%	-39.22%
Return on Invested Capital (ROIC)	-	-	-	-87.57%	-161.98%	-160.12%	-62.46%	-55.33%
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.03x	0.05x	0.05x
Interest Coverage	-	-	-	-	-	-155.83x	-55.78x	-61.14x
FCF Conversion	0.96x	0.06x	0.81x	0.89x	0.79x	0.83x	0.96x	0.91x

Frequently Asked Questions

Growth & Financials

Akero Therapeutics, Inc. (AKRO) grew revenue by 0.0% over the past year. Growth has been modest.

Akero Therapeutics, Inc. (AKRO) reported a net loss of $292.8M for fiscal year 2024.

Dividend & Returns

Akero Therapeutics, Inc. (AKRO) has a return on equity (ROE) of -39.2%. Negative ROE indicates the company is unprofitable.

Akero Therapeutics, Inc. (AKRO) had negative free cash flow of $250.2M in fiscal year 2024, likely due to heavy capital investments.